Literature DB >> 17998321

Ursodeoxycholic acid in chronic hepatitis C.

Raoul Poupon1, Lawrence Serfaty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17998321      PMCID： PMC2095696          DOI： 10.1136/gut.2007.130484

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  19 in total

Review 1.  Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways.

Authors:  M Eugenia Guicciardi; Gregory J Gores
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

2.  The cirrhotic hepatocyte: navigating between Scylla and Charybdis.

Authors:  Han Moshage
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

3.  Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism.

Authors:  Dalliah Black; Mark A Bird; Charles M Samson; Suzanne Lyman; Patty A Lange; Laura W Schrum; Ting Qian; J J Lemasters; David A Brenner; Richard A Rippe; Kevin E Behrns
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

4.  From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament.

Authors:  I Makino; H Tanaka
Journal:  J Gastroenterol Hepatol       Date:  1998-06       Impact factor: 4.029

5.  Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.

Authors:  Liang Qiao; Adly Yacoub; Elaine Studer; Seema Gupta; Xin Yan Pei; Steven Grant; Philip B Hylemon; Paul Dent
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

6.  Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Authors:  H Yoshida; Y Shiratori; M Moriyama; Y Arakawa; T Ide; M Sata; O Inoue; M Yano; M Tanaka; S Fujiyama; S Nishiguchi; T Kuroki; F Imazeki; O Yokosuka; S Kinoyama; G Yamada; M Omata
Journal:  Ann Intern Med       Date:  1999-08-03       Impact factor: 25.391

7.  Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice.

Authors:  Michele Barone; Eugenio Maiorano; Roberta Ladisa; Rosario Cuomo; Antonia Pece; Pasquale Berloco; Maria Lucia Caruso; Anna Maria Valentini; Achille Iolascon; Antonio Francavilla; Alfredo Di Leo; Enzo Ierardi
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats.

Authors:  Kenji Oyama; Goshi Shiota; Hisao Ito; Yoshikazu Murawaki; Hironaka Kawasaki
Journal:  Carcinogenesis       Date:  2002-05       Impact factor: 4.944

9.  Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.

Authors:  P Mathurin; J Moussalli; J F Cadranel; V Thibault; F Charlotte; P Dumouchel; A Cazier; J M Huraux; B Devergie; M Vidaud; P Opolon; T Poynard
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

10.  The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial.

Authors:  A F Attili; A Rusticali; M Varriale; L Carli; A M Repice; F Callea
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083
View more
  1 in total

1.  A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients.

Authors:  Shuichi Sato; Tatsuya Miyake; Hiroshi Tobita; Naoki Oshima; Junichi Ishine; Takuya Hanaoka; Yuji Amano; Yoshikazu Kinoshita
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.